223 related articles for article (PubMed ID: 19821025)
1. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.
Murrow LM; Garimella SV; Jones TL; Caplen NJ; Lipkowitz S
Breast Cancer Res Treat; 2010 Jul; 122(2):347-57. PubMed ID: 19821025
[TBL] [Abstract][Full Text] [Related]
2. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.
Garimella SV; Rocca A; Lipkowitz S
Mol Cancer Res; 2012 Jan; 10(1):75-85. PubMed ID: 22112940
[TBL] [Abstract][Full Text] [Related]
3. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
Ghiasi N; Habibagahi M; Rosli R; Ghaderi A; Yusoff K; Hosseini A; Abdullah S; Jaberipour M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6605-11. PubMed ID: 24377575
[TBL] [Abstract][Full Text] [Related]
4. Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.
Aka Y; Karakas B; Acikbas U; Basaga H; Gul O; Kutuk O
Int J Biochem Cell Biol; 2021 Aug; 137():106028. PubMed ID: 34171479
[TBL] [Abstract][Full Text] [Related]
5. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
6. Functional kinomics identifies candidate therapeutic targets in head and neck cancer.
Moser R; Xu C; Kao M; Annis J; Lerma LA; Schaupp CM; Gurley KE; Jang IS; Biktasova A; Yarbrough WG; Margolin AA; Grandori C; Kemp CJ; Méndez E
Clin Cancer Res; 2014 Aug; 20(16):4274-88. PubMed ID: 25125259
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.
Garimella SV; Gehlhaus K; Dine JL; Pitt JJ; Grandin M; Chakka S; Nau MM; Caplen NJ; Lipkowitz S
Breast Cancer Res; 2014 Apr; 16(2):R41. PubMed ID: 24745479
[TBL] [Abstract][Full Text] [Related]
8. Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.
Kuzu OF; Gowda R; Sharma A; Noory MA; Kardos G; Madhunapantula SV; Drabick JJ; Robertson GP
Cancer Biol Ther; 2018 Jan; 19(1):53-62. PubMed ID: 28853983
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
[TBL] [Abstract][Full Text] [Related]
10. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
11. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
[TBL] [Abstract][Full Text] [Related]
12. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
13. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.
Rahman M; Davis SR; Pumphrey JG; Bao J; Nau MM; Meltzer PS; Lipkowitz S
Breast Cancer Res Treat; 2009 Jan; 113(2):217-30. PubMed ID: 18266105
[TBL] [Abstract][Full Text] [Related]
14. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
[TBL] [Abstract][Full Text] [Related]
15. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
16. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
Chang Q; Chandrashekhar M; Ketela T; Fedyshyn Y; Moffat J; Hedley D
Cell Cycle; 2016; 15(4):593-604. PubMed ID: 26890070
[TBL] [Abstract][Full Text] [Related]
17. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
19. Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cells.
Pappano WN; Zhang Q; Tucker LA; Tse C; Wang J
BMC Cancer; 2014 Jun; 14():430. PubMed ID: 24927813
[TBL] [Abstract][Full Text] [Related]
20. Targeting WEE1 Kinase in Cancer.
Matheson CJ; Backos DS; Reigan P
Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
